Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Pridinol (ATC-Code: M03BX03) innerhalb des Zeitraumes vom 01.11.2026 bis zum 31.10.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

AOK Niedersachsen. The health insurance fund intends to conclude, until the entry into force of exclusive contracts following a public tender in accordance with the provisions of Part 4 of the GWB, non-exclusive medicinal product rebate contracts for the active ingredient Pridinol (ATC code: M03BX03) with as many market participants as possible (pharmaceutical entrepreneurs or associations of pharmaceutical entrepreneurs) under the so-called “open-house model”. AOK Niedersachsen will not make a selection decision and will submit an identical contract offer to every interested pharmaceutical company. Under the open-house model, uniform conditions apply to all participants. Contract content, terms and conditions, and access procedures are uniform—individual negotiations are generally not conducted. The contract terms are a maximum of twenty-four months; the earliest contract start date is 01.11.2026. All contracts end no later than 31.10.2028, regardless of the date on which the respective contract is concluded. Accession and/or conclusion of a contract may take place within the twenty-four-month period, each time on the first day of a month. There is a right of termination, each…

TENDER BRIEF

TENDER DOCUMENTS